SWK Holdings Corporation Announces Financial Results for Fourth Quarter 2024

Rhea-AI Summary

SWK Holdings (NASDAQ:SWKH) reported strong financial results for Q4 2024, with GAAP net income reaching $5.9 million ($0.48 per diluted share), up from $2.8 million in Q4 2023. Total revenue increased 25% to $12.4 million.

Key financial metrics include:

• Finance receivables segment revenue up 11.6% to $10.3 million
• Net finance receivables of $277.8 million, up 1.2% year-over-year
• Effective yield increased to 15.5%, up 150 basis points
• GAAP book value per share rose 5% to $23.45
• Non-GAAP tangible financing book value per share increased 8.3% to $21.15

The company monetized its performing royalty portfolio for approximately $51.3 million and plans to declare a dividend upon closing the final transaction. Portfolio improvements include successful workout conclusions and new financing agreements, including a $15 million commitment with Impedimed and an expanded $30 million credit facility with Eton.

Positive

• GAAP net income doubled to $5.9 million in Q4 2024 vs Q4 2023
• Total revenue increased 25% year-over-year to $12.4 million
• Effective yield improved by 150 basis points to 15.5%
• Book value per share increased 5% to $23.45
• Monetization of royalty portfolio for $51.3 million with planned dividend distribution
• Highest loan portfolio risk scoring achieved

Negative

• Three finance receivables remain in nonaccrual status worth $13.8 million
• Modest 1.2% growth in net finance receivables year-over-year

Insights

Financial Analyst

SWK Holdings' Q4 2024 results demonstrate strong financial performance with GAAP net income more than doubling to $5.9 million compared to $2.8 million in Q4 2023. The company's finance receivables segment showed adjusted non-GAAP net income of $6.2 million, up 68% year-over-year.

Revenue growth was robust at 25%, reaching $12.4 million for the quarter. The effective yield improved significantly to 15.5%, a 150 basis point increase from Q4 2023, indicating better returns on their financing portfolio.

The company continues to strengthen its balance sheet with GAAP book value per share increasing 5% to $23.45 and non-GAAP tangible financing book value rising 8.3% to $21.15.

SWK's strategic portfolio management is evident in their monetization of the performing royalty portfolio for approximately $51.3 million at a premium to book value. This transaction, along with planned dividend distributions, demonstrates a clear focus on shareholder returns.

The company has also made significant progress in resolving troubled assets, concluding three workouts and eliminating exposure to Biolase, Exeevo, and Trio Healthcare. Meanwhile, SWK continues to expand its loan portfolio with new commitments, including a $15 million financing agreement with Impedimed in Q1 2025.

This combination of improved financial metrics, successful workouts, new originations, and shareholder return initiatives positions SWK for continued growth in its specialty finance niche focusing on life science companies.

Conference Call Scheduled for Thursday, March 20, 2025, at 09:00 a.m. CST

Corporate Highlights

• Fourth quarter 2024 GAAP net income was $5.9 million, compared with GAAP net income of $2.8 million for the fourth quarter 2023.

• Fourth quarter 2024 finance receivables segment adjusted non-GAAP net income was $6.2 million, compared with adjusted non-GAAP net income of $3.7 million for the fourth quarter 2023.

• As of December 31, 2024, net finance receivables were $277.8 million, a 1.2% increase from December 31, 2023.

• The fourth quarter 2024 effective yield was 15.5%, a 150 basis points increase from fourth quarter 2023.

• As of December 31, 2024, GAAP book value per share was $23.45, a 5.0% increase from $22.33 on December 31, 2023.

• As of December 31, 2024, non-GAAP tangible financing book value per share was $21.15, an 8.3% increase from $19.53 as of December 31, 2023.

• In March 2025, through two transactions SWK monetized its performing royalty portfolio for approximately $51.3 million and anticipates declaring a dividend on the closing of the larger transaction.

DALLAS, TX / ACCESS Newswire / March 19, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the fourth quarter ended December 31, 2024.

"For the fourth quarter 2024, SWK's core Finance Receivables segment reported an 11.6% increase in revenue to $10.3 million compared to the same period in the prior year. SWK's finance segment generated $8.2 million of pre-tax GAAP net income and $6.2 million of adjusted non-GAAP net income.

SWK CEO Jody Staggs said "During the fourth quarter, we closed an up to $8.0 million term loan with Triple Ring and expanded our credit facility with Eton to $30.0 million. In February 2025, we closed a $15.0 million financing commitment with Impedimed.

Mr. Staggs added, "Improved operating results and capital raises at multiple borrowers combined with the conclusion of three workouts has led to our highest loan portfolio risk scoring since we have tracked the metric. The strength of our loan portfolio coupled with the monetization of our performing royalty portfolio at a slight premium to book value underpin the $21.15 of non-GAAP tangible financing book value per share, which excludes any value from our Enteris subsidiary. During the fourth quarter and year-to-date we have returned value to shareholders through our ongoing stock buyback program and anticipate declaring a dividend upon the closing of the final royalty monetization transaction, which is expected over the next two weeks"

Fourth Quarter 2024 Financial Results

For the fourth quarter 2024, SWK reported total revenue of $12.4 million, a 25.0%increase compared to $9.9 million for the fourth quarter 2023. The $2.5 million increase in revenue for the three months ended December 31, 2024 mainly consisted of a $1.1 million increase in Finance Receivables segment revenue and a $1.4 million increase in Pharmaceutical Development segment revenue.

Income before income tax expense for the quarter was $8.6 million and $0.6 million for the three months ended December 31, 2024 and 2023, respectively. Fourth quarter 2024 income before income tax expense benefited from a $2.5 million increase in consolidated revenue from interest and fees earned due to funding new loans and early loan payoffs, $2.2 million of unrealized gains on warrants, a $1.1 million gain on the extinguishment of the FC2 royalty, a $0.4 million decrease in the provision for credit losses, and a reduction of depreciation and amortization expense of $0.4 million.

GAAP net income for the quarter ended December 31, 2024, increased to $5.9 million, or $0.48 per diluted share, from $2.8 million, or $0.23 per diluted share, for the fourth quarter 2023.

For the fourth quarter 2024, non-GAAP adjusted net income was $6.6 million, or $0.54 per share. Non-GAAP adjusted net income for the Finance Receivables segment was $6.2 million, an increase from $3.7 million for the fourth quarter 2023.

Total investment assets (defined as finance receivables, marketable investments, and warrant assets less the allowance for credit losses) were $282.7 million as of December 31, 2024, a 2.3% increase compared with total investment assets of $276.3 million as of December 31, 2023. The allowance for credit losses at quarter's end totaled $11.2 million, a decrease of $2.7 million from the fourth quarter of 2023 driven by the conclusion of three workouts as well as the repayment of financing receivables partially offset by the origination of new finance receivables.

GAAP book value per share was $23.45 as of December 31, 2024, a 5.0% increase compared to $22.33 as of December 31, 2023. Non-GAAP tangible financing book value per share totaled $21.15, an 8.3% increase compared to $19.53 at December 31, 2023. Management views non-GAAP tangible financing book value per share as a relevant metric to value the Company's core finance receivable business. Non-GAAP tangible financing book value per share removes the value of the deferred tax assets and Enteris net asset value.

Portfolio Status

During the fourth quarter, SWK closed a term loan with Triple Ring totaling $8.0 million, expanded the credit facility with Eton to $30.0 million, advanced $5.0 million to existing borrower Journey Medical, $2.5 million to existing borrower SKNV, $2.5 million to existing borrower MedMinder, and $0.6 million to existing borrower Biotricity. During the first quarter of 2025, SWK closed a $15.0 million financing agreement with Impedimed.

During the fourth quarter, Veru made a $4.2 million payment to extinguish the FC2 residual royalty and in January 2025 Moleculight made a final payment to SWK totaling $12.2 million, fully satisfying its outstanding obligation. In March 2025, ANI Pharmaceuticals exercised a buyout option on the Iluvien royalty by making a $17.25 million payment to SWK.

During the fourth quarter, SWK received a $13.0 million payment from the Biolase bankruptcy estate and in February 2025 SWK received an additional $1.0 million. SWK may receive a final distribution from the Biolase bankruptcy estate, however, given uncertainty of the likelihood and amount of any distribution, as of December 31, 2024 SWK wrote-off the remaining Biolase finance receivable. In the fourth quarter SWK received a $3.4 million net payment from Exeevo and in the first quarter of 2025 SWK received additional net payments towards the Exeevo loan totaling $1.2 million. During the fourth quarter SWK received a $1.9 million payment from Trio Healthcare. SWK has no remaining balance sheet exposure to Biolase, Exeevo, or Trio Healthcare.

The fourth quarter 2024 effective yield was 15.5%, a 150 basis points increase from 14.0% in fourth quarter 2023. The effective yield is the rate at which income is expected to be recognized if payments are received pursuant to the terms of the finance receivables. The fourth quarter 2024 realized yield was 14.7%, a 60 basis point increase from 14.1% in fourth quarter 2023. The realized yield is inclusive of all fees, including all realized unamortized fees, amendment fees, and prepayment fees, and is calculated based on the simple average of finance receivables at the beginning and end of the period. The realized yield may differ from the effective yield due to actual cash collections being greater or lesser than modeled.

As of December 31, 2024, the Company had three finance receivables in nonaccrual status: (1) the Flowonix Medical, Inc. ("Flowonix") royalty, with a carrying value of $8.4 million; (2) the Ideal Implant, Inc. ("Ideal") royalty, with a carrying value of $3.1 million; and (3) the Best ABT, Inc. ("Best") royalty, with a carrying value of $2.3 million.

As of December 31, 2024, the Company had $5.8 million of unfunded commitments.

Total portfolio investment activity for the three months ended December 31, 2024, and 2023 was as follows (in thousands):

Adjusted Non-GAAP Net Income

The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the three-month periods ended December 31, 2024 and 2023. The table eliminates provisions for income taxes, non-cash mark-to-market changes on warrant assets and equity securities, amortization of Enteris intangible assets, and foreign currency transaction gains and losses.

In the table above, management has deducted the following non-cash items: (i) change in the fair-market value of equities and warrants, as mark-to-market changes are non-cash, (ii) income taxes, as the Company has substantial net operating losses to offset against future income, (iii) amortization expense associated with Enteris intangible assets, (iv) (gain) loss on remeasurement of contingent consideration, (v) goodwill impairment, and (vi) foreign currency (gains) losses.

Finance Receivables Adjusted Non-GAAP Net Income

The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income tax expense, listed in the table above, to the non-GAAP adjusted net income for the Finance Receivable segment for the three-month periods ended December 31, 2024 and 2023. The table eliminates Enteris operating loss. The adjusted income before income tax expense is derived in the table above and eliminates income tax expense, non-cash mark-to-market changes on equity securities, amortization of Enteris intangible assets, foreign currency transaction (gains) losses and any non-cash impact on the remeasurement of contingent consideration.

Non-GAAP Tangible Finance Book Value Per Share

The following table provides a reconciliation of SWK's GAAP book value per share to its non-GAAP tangible finance book value per share as of December 31, 2024 and 2023. The table eliminates the deferred tax assets, intangible assets, goodwill, Enteris property and equipment and acquisition-related contingent consideration (in thousands, except per share data):

Non-GAAP Financial Measures

This release includes non-GAAP adjusted net income, non-GAAP finance receivable segment net income, and non-GAAP tangible financing book value per share, which are metrics that are not compliant with generally accepted accounting principles in the United States (GAAP).

Non-GAAP adjusted net income is adjusted for certain items (including (i) changes in the fair-market value of public equity-related assets and SWK's warrant assets as mark-to-market changes are non-cash, (ii) income taxes as the Company has substantial net operating losses to offset against future income, (iii) changes in the fair-market value of contingent consideration associated with the Enteris acquisition as these changes are non-cash, and (iv) depreciation and amortization expenses, primarily associated with the Enteris acquisition.

In addition to the adjustments noted above, non-GAAP finance receivable segment net income also excludes Enteris operating losses.

Non-GAAP tangible financing book value per share excludes the deferred tax asset, intangible assets, goodwill, Enteris PP&E, and contingent consideration associated with the Enteris transaction.

These non-GAAP measures may not be directly comparable to similar measures used by other companies in the Company's industry, as other companies may define such measures differently. Management believes that these measures are useful to investors and management in understanding our ongoing operations and in analysis of ongoing operating trends and provides useful additional information relating to our operations and financial condition. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to better understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Further, non-GAAP financial measures, even if similarly titled, may not be calculated in the same manner by all companies, and therefore should not be compared.

Conference Call Information

SWK Holdings will host a conference call on March 20, 2025, at 9:00 a.m. CST, to discuss its corporate and financial results for the fourth quarter 2024.

Interested participants and investors may access the call via the numbers below:

1. 888-506-0062 (U.S.)

2. 973-528-0011 (International)

The participant Access Code is 698628 or ask for the SWK Holdings call

An archive of the webcast will remain available on the SWK Holdings' website for 12 months, starting later that day. https://investors.swkhold.com/events

About SWK Holdings Corporation

SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million. SWK also owns Enteris BioPharma, a clinical development and manufacturing organization providing development services to pharmaceutical partners. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.

Safe Harbor For Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For more information, please contact:

Investor Relations and Media
Susan Xu
728-323-0959
investorrelations@swkhold.com

SOURCE: SWK Holdings Corp.

View the original press release on ACCESS Newswire

FAQ

What was SWK Holdings' (SWKH) Q4 2024 net income and how did it compare to Q4 2023?

SWKH's Q4 2024 GAAP net income was $5.9 million ($0.48 per diluted share), more than double the Q4 2023 net income of $2.8 million ($0.23 per diluted share).

How much did SWKH's royalty portfolio monetization generate in March 2025?

SWKH monetized its performing royalty portfolio through two transactions for approximately $51.3 million.

What was SWKH's book value per share as of December 31, 2024?

SWKH's GAAP book value per share was $23.45, representing a 5.0% increase from $22.33 on December 31, 2023.

What new financing commitments did SWKH secure in Q4 2024 and early 2025?

SWKH secured an $8 million term loan with Triple Ring, expanded Eton credit facility to $30 million, and closed a $15 million financing agreement with Impedimed in early 2025.

What was SWKH's effective yield in Q4 2024 compared to Q4 2023?

The effective yield in Q4 2024 was 15.5%, representing a 150 basis points increase from 14.0% in Q4 2023.